基因分型市场 - 全球产业规模、份额、趋势、机会和预测，按产品、技术、应用、最终用途、地区和竞争细分，2020-2030 年预测

2024 年全球基因分型市场价值为 162.5 亿美元，预计到 2030 年将达到 268.7 亿美元，预测期内复合年增长率为 8.74%。全球基因分型市场是生物技术和生命科学领域中一个充满活力且快速成长的领域。基因分型是一种确定个体基因组成（包括其 DNA 序列的变化）的过程。这些资讯对于个人化医疗和疾病研究到农业和祖先测试等广泛的应用都至关重要。

预计基因分型市场将经历成长，这得益于政府资金的增加，特别是政府机构对基因组研究的资助，以及製药和生物技术公司为加速研究所做的贡献。一个值得关注的例子是美国国立卫生研究院（NIH）于2018年9月向「我们所有人研究计画」拨款2,860万美元，用于在全美建立三个致力于精准医学研究的基因组中心。

全球癌症和遗传疾病等慢性病的增多，将推动基于基因型的诊断测试的需求。例如，世界卫生组织 (WHO) 报告称，2020 年全球诊断出 1,910 万例新癌症病例。此外，人类乳突病毒 (HPV) 和乙型肝炎病毒 (HBV)/丙型肝炎病毒 (HCV) 等致癌病毒造成了全球约 20% 的癌症相关死亡。由于人口增长和老化，未来二十年癌症病例数预计将增加约 70%。因此，癌症发生率的上升预计将成为该市场的重要驱动力。

主要市场驱动因素

基因分型技术的进步

主要市场挑战

数据管理和解释

主要市场趋势

多组学方法的整合

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球基因分型市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按产品（仪器、试剂和试剂盒、软体和服务）
  • 依技术分类（PCR、毛细管电泳、微阵列、定序、质谱、其他）
  • 按应用（药物基因组学、诊断和个人化医疗、农业生物技术、动物遗传学、其他）
  • 按最终用途（製药和生物製药公司、诊断和研究实验室、学术机构、其他）
  • 按地区
  • 按公司分类（2024）
• 产品市场图
  • 按产品
  • 依技术分类
  • 按应用
  • 按最终用途
  • 按地区

第 6 章：北美基因分型市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲基因分型市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 法国
  • 义大利
  • 西班牙

第 8 章：亚太地区基因分型市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 日本
  • 印度
  • 澳洲
  • 韩国

第 9 章：南美洲基因分型市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲基因分型市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 科威特

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 合併与收购
• 产品发布

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Thermo Fisher Scientific Inc.
• Illumina Inc.
• QIAGEN NV
• F Hoffmann-La Roche AG
• Danaher Corporation
• Agilent Technologies, Inc.
• Eurofins Scientific Inc.
• GE HealthCare
• Bio-Rad Laboratories Inc.
• Standard BioTools(TM)

第 15 章：策略建议

第16章调查会社について・免责事项

Global Genotyping Market was valued at USD 16.25 billion in 2024 and is expected to reach USD 26.87 billion by 2030 with a CAGR of 8.74% during the forecast period. The global genotyping market is a dynamic and rapidly growing sector within the field of biotechnology and life sciences. Genotyping is the process of determining an individual's genetic makeup, including variations in their DNA sequence. This information is crucial for a wide range of applications, from personalized medicine and disease research to agriculture and ancestry testing.

The genotyping market is expected to experience growth driven by increased government funding, particularly for genomic research from governmental bodies, as well as contributions from pharmaceutical and biotechnology companies, aimed at expediting research. A noteworthy example of this is the National Institutes of Health (NIH) granting USD 28.6 million in September 2018 to the "All of Us Research Program" for establishing three genome centers across the United States dedicated to precision medicine research.

The global rise in chronic diseases, including cancer and genetic disorders, is set to fuel the demand for genotypic-based diagnostic testing. To illustrate, the World Health Organization (WHO) reported 19.1 million new cancer cases diagnosed worldwide in 2020. Moreover, cancer-causing viruses like Human Papilloma Virus (HPV) and Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) are responsible for approximately 20% of cancer-related deaths on a global scale. The number of cancer cases is projected to increase by roughly 70% over the next two decades, driven by population growth and aging. Therefore, the increasing prevalence of cancer is expected to be a significant driving force for this market.

Key Market Drivers

Advancements in Genotyping Technologies

Genotyping, the process of analyzing an individual's genetic makeup, is undergoing a revolution thanks to advancements in genotyping technologies. These innovations have not only enhanced the efficiency and accuracy of genotyping but also expanded its applications across various sectors, including healthcare, research, agriculture, and personalized medicine. One of the most significant factors propelling the genotyping market forward is the advent of high-throughput genotyping platforms. These platforms can analyze thousands or even millions of genetic markers in a single experiment, significantly increasing the speed and cost-effectiveness of genotyping. Researchers and clinicians can process larger datasets quickly, making genotyping accessible for a wide range of applications.

Next-generation sequencing, or NGS, is a game-changer in genotyping. It allows for the simultaneous sequencing of a person's entire genome, making it possible to identify even the rarest genetic variations. NGS is not only faster and more affordable than traditional Sanger sequencing, but it also generates vast amounts of data, enabling comprehensive genomic analysis. This technology has become essential in research, clinical diagnostics, and personalized medicine. Advancements in genotyping technologies have significantly improved the accuracy and resolution of genotyping results. Single nucleotide polymorphism (SNP) genotyping, for example, has become highly accurate, making it an invaluable tool in identifying genetic markers associated with diseases, drug responses, and other traits. This precision has bolstered the credibility of genotyping in both research and clinical applications.

Key Market Challenges

Data Management and Interpretation

One of the primary challenges in the genotyping market is the management and interpretation of the massive amounts of genetic data generated. Genotyping technologies, especially high-throughput platforms and next-generation sequencing, produce enormous datasets. The efficient analysis and interpretation of this data requires robust bioinformatics tools and skilled personnel, making data management a significant hurdle.

Key Market Trends

Integration of Multi-Omics Approaches

Genotyping is increasingly being integrated with other omics technologies such as proteomics and metabolomics. This holistic approach allows researchers to gain a more comprehensive understanding of biological systems. By analyzing genetic, protein, and metabolic data together, researchers can uncover intricate relationships and potential biomarkers for various diseases and conditions.

Key Market Players

• Thermo Fisher Scientific Inc.
• Illumina Inc.
• QIAGEN N.V.
• F Hoffmann-La Roche AG
• Danaher Corporation
• Agilent Technologies, Inc.
• Eurofins Scientific Inc.
• GE HealthCare
• Bio-Rad Laboratories Inc.
• Standard BioTools(TM)

Report Scope:

In this report, the Global Genotyping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genotyping Market, By Product:

• Instruments
• Reagents & Kits
• Software and Services

Genotyping Market, By Technology:

• PCR
• Capillary Electrophoresis
• Microarrays
• Sequencing
• Mass Spectrometry
• Others

Genotyping Market, By Application:

• Pharmacogenomics
• Diagnostics and Personalized Medicine
• Agricultural Biotechnology
• Animal Genetics
• Others

Genotyping Market, By End Use:

• Pharmaceutical and Biopharmaceutical Companies
• Diagnostics and Research Laboratories
• Academic Institutes
• Others

Genotyping Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genotyping Market.

Available Customizations:

Global Genotyping market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genotyping Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Reagents & Kits, Software and Services)
  • 5.2.2. By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others)
  • 5.2.3. By Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others)
  • 5.2.4. By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Product
  • 5.3.2. By Technology
  • 5.3.3. By Application
  • 5.3.4. By End Use
  • 5.3.5. By Region

6. North America Genotyping Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product (Instruments, Reagents & Kits, Software and Services)
  • 6.2.2. By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others)
  • 6.2.3. By Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others)
  • 6.2.4. By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes, Others)
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Genotyping Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End Use
  • 6.3.2. Canada Genotyping Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End Use
  • 6.3.3. Mexico Genotyping Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End Use

7. Europe Genotyping Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product (Instruments, Reagents & Kits, Software and Services)
  • 7.2.2. By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others)
  • 7.2.3. By Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others)
  • 7.2.4. By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes, Others)
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Genotyping Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End Use
  • 7.3.2. United Kingdom Genotyping Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End Use
  • 7.3.3. France Genotyping Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Genotyping Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Genotyping Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End Use

8. Asia-Pacific Genotyping Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product (Instruments, Reagents & Kits, Software and Services)
  • 8.2.2. By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others)
  • 8.2.3. By Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others)
  • 8.2.4. By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes, Others)
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Genotyping Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End Use
  • 8.3.2. Japan Genotyping Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End Use
  • 8.3.3. India Genotyping Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End Use
  • 8.3.4. Australia Genotyping Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End Use
  • 8.3.5. South Korea Genotyping Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End Use

9. South America Genotyping Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product (Instruments, Reagents & Kits, Software and Services)
  • 9.2.2. By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others)
  • 9.2.3. By Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others)
  • 9.2.4. By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes, Others)
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Genotyping Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End Use
  • 9.3.2. Argentina Genotyping Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End Use
  • 9.3.3. Colombia Genotyping Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End Use

10. Middle East and Africa Genotyping Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product (Instruments, Reagents & Kits, Software and Services)
  • 10.2.2. By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others)
  • 10.2.3. By Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others)
  • 10.2.4. By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes, Others)
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Genotyping Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End Use
  • 10.3.2. Saudi Arabia Genotyping Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End Use
  • 10.3.3. UAE Genotyping Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End Use
  • 10.3.4. Kuwait Genotyping Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Product
      • 10.3.4.2.2. By Technology
      • 10.3.4.2.3. By Application
      • 10.3.4.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Thermo Fisher Scientific Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Illumina Inc.
• 14.3. QIAGEN N.V.
• 14.4. F Hoffmann-La Roche AG
• 14.5. Danaher Corporation
• 14.6. Agilent Technologies, Inc.
• 14.7. Eurofins Scientific Inc.
• 14.8. GE HealthCare
• 14.9. Bio-Rad Laboratories Inc.
• 14.10. Standard BioTools(TM)

15. Strategic Recommendations

16. About Us & Disclaimer